Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-EDV-D682/GC in metastatic pancreatic ductal adenocarcinoma
NCT07049055Phase 2Recruiting
- Sponsor
- EnGeneIC
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Modality
- Nanoparticles, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of EGFR(V)-EDV-PNU, EDV-GC in pancreatic ductal adenocarcinoma (PDAC), sponsored by EnGeneIC. Started Jan 2026; status: recruiting.
02
Drugs
EGFR(V)-EDV-PNUEDV-GC
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07049055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049055.